Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revolade Tablets Specified Drug-use Survey in ATG-naive Pediatric Aplastic Anemia
jRCT2031230694Recruiting
- Sponsor
- Novartis
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of eltrombopag in aplastic anemia, sponsored by Novartis. Primary endpoint: Serious adverse events. Started Apr 2024; status: recruiting.
02
Drugs
eltrombopag
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on jRCT2031230694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230694.